Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis[J]. Cancer Res, 2000, 60(3): 722-727.
[2]
Folkman J. Angiogenesis in cancer, vascular, rhe-umatoid and other disease[J]. Nat Med, 1995, 1: 27-30.
[3]
Luan Y, Xu W. The structure and main functions of aminopeptidase N[J]. Curr Med Chem, 2007, 14: 639-647.
[4]
Fukasawa K, Fujii K, Saitoh Y, et al. Aminopeptidase N(APN/CD13)is selectively expressed in vascularendothelial cells and play a multiple roles in angiogenesis[J]. Cancer Letters, 2006, 243: 135-143.
[5]
Metaferia BB, Rittler M, Gheeya JS,et al. Synthesis of novel cyclic NGR/RGD peptide analogs via on resin click chemistry[J]. Bioorg Med Chem Lett, 2010, 20(24): 7 337-7 340.
[6]
Wadih A, Renata P, Erkki R. Cancer treatment by targeted drug delivery to tumor vasculature in mouse model[J]．Science, 1998, 279(16): 377-380．
[7]
Sacchi A, Gasparri A, Gallo-Stampino C, et al. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha[J]. Clin Cancer Res，2006, 12(1): 175-182.
Dreischalück J, Schwppe C, Spieker T, et al. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGRpeptides: activity and toxicity profile[J]. Int J Oncol, 2010, 37(6): 1 389-1 397.
Hui X, Han Y, Liang S，et al. Specific targeting of the vasculature of gastric cancer by a new tumor-homing peptide CGNSNPKSC[J]. J Control Release, 2008, 131(2): 86-93.
[12]
Thakur M, Kolan H, Rifat S, et al. Vapreotide labeled with Tc-99m for imaging tumors[J]. Int J Oncol, 1996, 9(3): 445-451.
[13]
Santoro A, Rimassa L, Sobrero AF, et al. Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy[J]. Eur J Cancer, 2010, 46(15): 2 746-2 752.
